Jdp patents expiration
1. Quzyttir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
| US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
| US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
| US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
| US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 4, 2022 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2019
Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
QUZYTTIR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic